BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23831920)

  • 1. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.
    Asmar F; Punj V; Christensen J; Pedersen MT; Pedersen A; Nielsen AB; Hother C; Ralfkiaer U; Brown P; Ralfkiaer E; Helin K; Grønbæk K
    Haematologica; 2013 Dec; 98(12):1912-20. PubMed ID: 23831920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis of genome‑wide gene expression and DNA methylation microarray of diffuse large B‑cell lymphoma with TET mutations.
    Liu P; Jiang W; Zhao J; Zhang H
    Mol Med Rep; 2017 Oct; 16(4):3777-3782. PubMed ID: 28731140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
    Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
    Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
    Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
    Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
    Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
    Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma.
    Nishizawa S; Sakata-Yanagimoto M; Hattori K; Muto H; Nguyen T; Izutsu K; Yoshida K; Ogawa S; Nakamura N; Chiba S
    Int J Hematol; 2017 Apr; 105(4):465-469. PubMed ID: 27921272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TET2 Promoter DNA Methylation and Expression in Childhood Acute Lymphoblastic Leukemia.
    Bahari G; Hashemi M; Naderi M; Taheri M
    Asian Pac J Cancer Prev; 2016; 17(8):3959-62. PubMed ID: 27644645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TET2 mutation in diffuse large B-cell lymphoma.
    Kubuki Y; Yamaji T; Hidaka T; Kameda T; Shide K; Sekine M; Kamiunten A; Akizuki K; Shimoda H; Tahira Y; Nakamura K; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Kitanaka A; Shimoda K
    J Clin Exp Hematop; 2017; 56(3):145-149. PubMed ID: 28331128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
    Dominguez PM; Ghamlouch H; Rosikiewicz W; Kumar P; Béguelin W; Fontán L; Rivas MA; Pawlikowska P; Armand M; Mouly E; Torres-Martin M; Doane AS; Calvo Fernandez MT; Durant M; Della-Valle V; Teater M; Cimmino L; Droin N; Tadros S; Motanagh S; Shih AH; Rubin MA; Tam W; Aifantis I; Levine RL; Elemento O; Inghirami G; Green MR; Figueroa ME; Bernard OA; Aoufouchi S; Li S; Shaknovich R; Melnick AM
    Cancer Discov; 2018 Dec; 8(12):1632-1653. PubMed ID: 30274972
    [No Abstract]   [Full Text] [Related]  

  • 10. Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations.
    Nielsen HM; Andersen CL; Westman M; Kristensen LS; Asmar F; Kruse TA; Thomassen M; Larsen TS; Skov V; Hansen LL; Bjerrum OW; Hasselbalch HC; Punj V; Grønbæk K
    Sci Rep; 2017 Jul; 7(1):6774. PubMed ID: 28754985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline TET2 loss of function causes childhood immunodeficiency and lymphoma.
    Stremenova Spegarova J; Lawless D; Mohamad SMB; Engelhardt KR; Doody G; Shrimpton J; Rensing-Ehl A; Ehl S; Rieux-Laucat F; Cargo C; Griffin H; Mikulasova A; Acres M; Morgan NV; Poulter JA; Sheridan EG; Chetcuti P; O'Riordan S; Anwar R; Carter CR; Przyborski S; Windebank K; Cant AJ; Lako M; Bacon CM; Savic S; Hambleton S
    Blood; 2020 Aug; 136(9):1055-1066. PubMed ID: 32518946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A primary role of TET proteins in establishment and maintenance of De Novo bivalency at CpG islands.
    Kong L; Tan L; Lv R; Shi Z; Xiong L; Wu F; Rabidou K; Smith M; He C; Zhang L; Qian Y; Ma D; Lan F; Shi Y; Shi YG
    Nucleic Acids Res; 2016 Oct; 44(18):8682-8692. PubMed ID: 27288448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
    Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
    Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TET2: A cornerstone in normal and malignant hematopoiesis.
    Kunimoto H; Nakajima H
    Cancer Sci; 2021 Jan; 112(1):31-40. PubMed ID: 33048426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of Tet proteins results in quantitative disparities during ESC differentiation partially attributable to alterations in gene expression.
    Reimer M; Pulakanti K; Shi L; Abel A; Liang M; Malarkannan S; Rao S
    BMC Dev Biol; 2019 Jul; 19(1):16. PubMed ID: 31286885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of TET2 in hematologic malignancies.
    Chiba S
    Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TET proteins and 5-methylcytosine oxidation in hematological cancers.
    Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
    Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
    Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
    Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
    Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
    Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
    Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
    Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.